Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-09-15
Target enrollment:
Participant gender:
Summary
This is a controlled, open-label, randomized phase- II trial (1:1 randomization)
investigating 5-FU + aflibercept and 5-FU + oxaliplatin in elderly and frail elderly patients
with mCRC scheduled to receive first line treatment.
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators:
Sanofi STABIL - Statistische und Biometrische Lösungen Trium Analysis Online GmbH